secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2022-10-04T23:59:59+00:00
Accession:  0001193125-22-257688
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant prices $75M stock offering at $6/share to fund IMVT-1402 development
-------------------------------------------------------------------------------

- Priced 12.5M shares at $6.00 per share; gross proceeds ~$75M before discounts.
- Investors include Logos Capital, Deep Track Capital, Frazier Life Sciences, TCGX, BVF, and Commodore Capital.
- Net proceeds to accelerate IMVT-1402 development, including a proposed pivotal trial.
- Existing cash plus offering proceeds expected to fund company into H2 2025.
- Offering expected to close Oct 6, 2022; SVB Securities and Truist Securities are joint bookrunners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000119312522257688/0001193125-22-257688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000119312522257688/d391688d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-257688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer